This Beverly JCG Insider Increased Their Holding By 93% Last Year
Looking at Beverly JCG Ltd.'s (Catalist:9QX ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
The Last 12 Months Of Insider Transactions At Beverly JCG
The insider Mark Jones made the biggest insider purchase in the last 12 months. That single transaction was for S$500k worth of shares at a price of S$0.0087 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of S$0.011. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
Mark Jones bought 119.20m shares over the last 12 months at an average price of S$0.0084. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
View our latest analysis for Beverly JCG
Beverly JCG is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Does Beverly JCG Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Beverly JCG insiders own 57% of the company, worth about S$5.8m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
What Might The Insider Transactions At Beverly JCG Tell Us?
It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Beverly JCG. Looks promising! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Our analysis shows 5 warning signs for Beverly JCG (4 make us uncomfortable!) and we strongly recommend you look at them before investing.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Asian Market Value Picks: 3 Companies That May Be Trading Below Intrinsic Estimates
Amidst global economic uncertainties and fluctuating trade policies, Asian markets have shown resilience, with varying impacts on indices across the region. This environment presents opportunities for discerning investors to explore stocks that may be trading below their intrinsic value, particularly those with strong fundamentals and potential for growth despite external pressures. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xi'an NovaStar Tech (SZSE:301589) CN¥155.51 CN¥309.46 49.7% SpiderPlus (TSE:4192) ¥506.00 ¥997.79 49.3% Ningbo Sanxing Medical ElectricLtd (SHSE:601567) CN¥22.88 CN¥45.72 50% Nanya Technology (TWSE:2408) NT$43.75 NT$87.13 49.8% Nan Ya Printed Circuit Board (TWSE:8046) NT$176.50 NT$350.51 49.6% Insource (TSE:6200) ¥926.00 ¥1843.53 49.8% H.U. Group Holdings (TSE:4544) ¥3254.00 ¥6446.96 49.5% Elan (TSE:6099) ¥850.00 ¥1696.06 49.9% cottaLTD (TSE:3359) ¥441.00 ¥871.25 49.4% Astroscale Holdings (TSE:186A) ¥676.00 ¥1333.68 49.3% Click here to see the full list of 274 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Beijing HyperStrong Technology Overview: Beijing HyperStrong Technology Co., Ltd. designs, develops, integrates, and operates energy storage power stations across China, Europe, North America, and Australia with a market cap of CN¥16.64 billion. Operations: The company's revenue segments include the design, development, integration, and operation of energy storage power stations across its key markets in China, Europe, North America, and Australia. Estimated Discount To Fair Value: 37.2% Beijing HyperStrong Technology is trading at CN¥92.37, significantly below its estimated fair value of CN¥147.06, suggesting it may be undervalued based on cash flows. Its revenue and earnings are forecast to grow over 30% annually, outpacing the Chinese market's growth rates. However, its dividend yield of 1.19% is not well covered by free cash flows. Recent innovations like the HyperBlock M enhance its competitive edge in energy storage solutions through modularity and efficiency improvements. Upon reviewing our latest growth report, Beijing HyperStrong Technology's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of Beijing HyperStrong Technology stock in this financial health report. Shenzhen KSTAR Science and Technology Overview: Shenzhen KSTAR Science and Technology Co., Ltd. operates in the technology sector, focusing on power electronics and renewable energy solutions, with a market cap of CN¥13.86 billion. Operations: Unfortunately, the provided text does not contain specific revenue segment information for Shenzhen KSTAR Science and Technology Co., Ltd. Estimated Discount To Fair Value: 48.5% Shenzhen KSTAR Science and Technology is trading at CN¥23.8, well below its estimated fair value of CN¥46.24, indicating potential undervaluation based on cash flows. The company's revenue is projected to grow 22.3% annually, surpassing the Chinese market's average growth rate. Despite a forecasted earnings growth of 32.4%, profit margins have declined from last year, and the dividend track record remains unstable with recent reductions in payouts for 2024 dividends. The growth report we've compiled suggests that Shenzhen KSTAR Science and Technology's future prospects could be on the up. Click here to discover the nuances of Shenzhen KSTAR Science and Technology with our detailed financial health report. Qingdao Baheal Medical Overview: Qingdao Baheal Medical INC. is involved in the research, development, production, wholesale, and retail of pharmaceutical products across China, the United States, Hong Kong, and the United Kingdom with a market cap of CN¥11.77 billion. Operations: Qingdao Baheal Medical INC. generates revenue through its activities in the research, development, production, wholesale, and retail sectors of pharmaceutical products across several international markets including China, the United States, Hong Kong, and the United Kingdom. Estimated Discount To Fair Value: 18.5% Qingdao Baheal Medical, trading at CN¥22.39, is priced below its fair value estimate of CN¥27.46, reflecting potential undervaluation based on cash flows. Despite a volatile share price recently, earnings are projected to grow significantly at 20.05% annually over the next three years, although this lags behind the broader Chinese market's growth rate. The company affirmed a dividend payout for 2024, which may appeal to income-focused investors amid stable revenue growth projections of 13% per year. In light of our recent growth report, it seems possible that Qingdao Baheal Medical's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Qingdao Baheal Medical. Turning Ideas Into Actions Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 271 more companies for you to here to unveil our expertly curated list of 274 Undervalued Asian Stocks Based On Cash Flows. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688411 SZSE:002518 and SZSE:301015. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Glomac Berhad (KLSE:GLOMAC) shareholders have endured a 13% loss from investing in the stock a year ago
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. For example, the Glomac Berhad (KLSE:GLOMAC) share price is down 18% in the last year. That's well below the market decline of 1.8%. The silver lining (for longer term investors) is that the stock is still 1.7% higher than it was three years ago. Furthermore, it's down 12% in about a quarter. That's not much fun for holders. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Unfortunately Glomac Berhad reported an EPS drop of 34% for the last year. The share price fall of 18% isn't as bad as the reduction in earnings per share. So despite the weak per-share profits, some investors are probably relieved the situation wasn't more difficult. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. It might be well worthwhile taking a look at our free report on Glomac Berhad's earnings, revenue and cash flow. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Glomac Berhad the TSR over the last 1 year was -13%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence! A Different Perspective While the broader market gained around 1.8% in the last year, Glomac Berhad shareholders lost 13% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 5%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Glomac Berhad is showing 2 warning signs in our investment analysis , you should know about... Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
South Korea pledges to help companies cope with higher US tariffs
By Jihoon Lee SEOUL (Reuters) -South Korea will prepare measures to help companies cope with higher U.S. tariffs and expand into new markets, the Finance Ministry said on Tuesday, as it kicked off a task force to prepare the new administration's economic policy plans. On the domestic front, the government will come up with measures to boost short-term demand, as well as financial support for mid- to long-term technology development to enhance market competitiveness, it said in a statement. South Korea reached a trade deal with the U.S. last week, just days before President Donald Trump's threatened 25% tariff rate was due to come in on its exports to the United States. The trade deal set tariffs on exports from the Asian country at 15%, still higher than a baseline 10% rate and the near zero tariffs for exports under a Korea-U.S. free trade agreement. Still, topics left unresolved by the deal provide scope for more disputes as the two countries prepare for a summit between Trump and new South Korean President Lee Jae Myung in the coming weeks. Trump may use the summit to try to squeeze more concessions on areas such as defence costs and corporate investments, left out of the deal, while non-tariff barriers and currency could prove thorny issues, experts said. South Korea's Finance Ministry, however, sought to give a positive spin on the agreement. The deal reduced uncertainty over the trade environment, while a $350 billion investment package included in the deal will provide new business opportunities for companies, deepen economic cooperation between the two countries, and contribute to a more stable supply chain, the ministry said. The administration of President Lee also plans to prepare policy measures to foster new industries, such as artificial intelligence, semiconductors and "K-contents" and include them in economic growth strategies and budget plans due to be announced later this month. K-contents refers to a range of cultural and entertainment goods produced by the country ranging from K-pop to Korean dramas that have boomed globally. The ministry vowed to bring regulatory improvements to vitalise business activity, as it kicked off a meeting with the country's major business groups. Asia's fourth-largest economy grew in the second quarter at the fastest pace in more than a year on rebounding consumer spending and a surge in technology exports, but still faces headwinds from slowing global trade amid the sweeping tariffs. The International Monetary Fund last week raised its outlook for most advanced and emerging economies this year based on developments around U.S. tariff negotiations, but South Korea was among the exceptions, with its 2025 growth forecast revised down to 0.8% from 1.0%.
